The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia.
| Title: | The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia. |
|---|---|
| Authors: | Saunders, Stina, Gregory, Sarah, Clement, Matthew H. S., Birck, Cindy, van der Geyten, Serge, Ritchie, Craig W. |
| Source: | Frontiers in Neurology; 11/22/2022, Vol. 13, p1-13, 13p |
| Subject Terms: | ALZHEIMER'S disease, SECONDARY prevention, APOLIPOPROTEIN E4, SCIENTIFIC community, DRUGS, NEW trials |
| Company/Entity: | UNIVERSITY of Edinburgh |
| Abstract: | Introduction: Tens of millions of people worldwide will develop Alzheimer's disease (AD), and only by intervening early in the preclinical disease can we make a fundamental difference to the rates of late-stage disease where clinical symptoms and societal burdenmanifest. However, collectively utilizing data, samples, and knowledge amassed by large-scale projects such as the Innovative Medicines Initiative (IMI)-funded European Prevention of Alzheimer's Dementia (EPAD) program will enable the research community to learn, adapt, and implement change. Method: In the current article, we define and discuss the substantial assets of the EPAD project for the scientific community, patient population, and industry, describe the EPAD structure with a focus on how the public and private sector interacted and collaborated within the project, reflect how IMI specifically supported the achievements of the above, and conclude with a view for future. Results: The EPAD project was a €64-million investment to facilitate secondary prevention of AD dementia research. The project recruited over 2,000 research participants into the EPAD longitudinal cohort study (LCS) and included over 400 researchers from 39 partners. The EPAD LCS data and biobank are freely available and easily accessible via the Alzheimer's Disease Data Initiative's (ADDI) AD Workbench platform and the University of Edinburgh's Sample Access Committee. The trial delivery network established within the EPAD program is being incorporated into the truly global offering fromtheGlobal Alzheimer's Platform(GAP) for trial delivery, and the almost 100 early-career researchers who were part of the EPAD Academy will take forward their experience and learning from EPAD to the next stage of their careers. Discussion: Through GAP, IMI-Neuronet, and follow-on funding from the Alzheimer's Association for the data and sample access systems, the EPAD assets will be maintained and, as and when sponsors seek a new platform trial to be established, the learnings from EPAD will ensure that this can be developed to be even more successful than this first pan-European attempt. [ABSTRACT FROM AUTHOR] |
| Copyright of Frontiers in Neurology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Complementary Index |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edb&genre=article&issn=16642295&ISBN=&volume=13&issue=&date=20221122&spage=1&pages=1-13&title=Frontiers in Neurology&atitle=The%20European%20Prevention%20of%20Alzheimer%27s%20Dementia%20Programme%3A%20An%20Innovative%20Medicines%20Initiative-funded%20partnership%20to%20facilitate%20secondary%20prevention%20of%20Alzheimer%27s%20disease%20dementia.&aulast=Saunders%2C%20Stina&id=DOI:10.3389/fneur.2022.1051543 Name: Full Text Finder (for New FTF UI) (s8985755) Category: fullText Text: Find It @ SCU Libraries MouseOverText: Find It @ SCU Libraries |
|---|---|
| Header | DbId: edb DbLabel: Complementary Index An: 160664427 RelevancyScore: 957 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 957.27880859375 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Saunders%2C+Stina%22">Saunders, Stina</searchLink><br /><searchLink fieldCode="AR" term="%22Gregory%2C+Sarah%22">Gregory, Sarah</searchLink><br /><searchLink fieldCode="AR" term="%22Clement%2C+Matthew+H%2E+S%2E%22">Clement, Matthew H. S.</searchLink><br /><searchLink fieldCode="AR" term="%22Birck%2C+Cindy%22">Birck, Cindy</searchLink><br /><searchLink fieldCode="AR" term="%22van+der+Geyten%2C+Serge%22">van der Geyten, Serge</searchLink><br /><searchLink fieldCode="AR" term="%22Ritchie%2C+Craig+W%2E%22">Ritchie, Craig W.</searchLink> – Name: TitleSource Label: Source Group: Src Data: Frontiers in Neurology; 11/22/2022, Vol. 13, p1-13, 13p – Name: Subject Label: Subject Terms Group: Su Data: <searchLink fieldCode="DE" term="%22ALZHEIMER'S+disease%22">ALZHEIMER'S disease</searchLink><br /><searchLink fieldCode="DE" term="%22SECONDARY+prevention%22">SECONDARY prevention</searchLink><br /><searchLink fieldCode="DE" term="%22APOLIPOPROTEIN+E4%22">APOLIPOPROTEIN E4</searchLink><br /><searchLink fieldCode="DE" term="%22SCIENTIFIC+community%22">SCIENTIFIC community</searchLink><br /><searchLink fieldCode="DE" term="%22DRUGS%22">DRUGS</searchLink><br /><searchLink fieldCode="DE" term="%22NEW+trials%22">NEW trials</searchLink> – Name: SubjectCompany Label: Company/Entity Group: Su Data: <searchLink fieldCode="CO" term="%22UNIVERSITY+of+Edinburgh%22">UNIVERSITY of Edinburgh</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Introduction: Tens of millions of people worldwide will develop Alzheimer's disease (AD), and only by intervening early in the preclinical disease can we make a fundamental difference to the rates of late-stage disease where clinical symptoms and societal burdenmanifest. However, collectively utilizing data, samples, and knowledge amassed by large-scale projects such as the Innovative Medicines Initiative (IMI)-funded European Prevention of Alzheimer's Dementia (EPAD) program will enable the research community to learn, adapt, and implement change. Method: In the current article, we define and discuss the substantial assets of the EPAD project for the scientific community, patient population, and industry, describe the EPAD structure with a focus on how the public and private sector interacted and collaborated within the project, reflect how IMI specifically supported the achievements of the above, and conclude with a view for future. Results: The EPAD project was a €64-million investment to facilitate secondary prevention of AD dementia research. The project recruited over 2,000 research participants into the EPAD longitudinal cohort study (LCS) and included over 400 researchers from 39 partners. The EPAD LCS data and biobank are freely available and easily accessible via the Alzheimer's Disease Data Initiative's (ADDI) AD Workbench platform and the University of Edinburgh's Sample Access Committee. The trial delivery network established within the EPAD program is being incorporated into the truly global offering fromtheGlobal Alzheimer's Platform(GAP) for trial delivery, and the almost 100 early-career researchers who were part of the EPAD Academy will take forward their experience and learning from EPAD to the next stage of their careers. Discussion: Through GAP, IMI-Neuronet, and follow-on funding from the Alzheimer's Association for the data and sample access systems, the EPAD assets will be maintained and, as and when sponsors seek a new platform trial to be established, the learnings from EPAD will ensure that this can be developed to be even more successful than this first pan-European attempt. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Group: Ab Data: <i>Copyright of Frontiers in Neurology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=160664427 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.3389/fneur.2022.1051543 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 13 StartPage: 1 Subjects: – SubjectFull: UNIVERSITY of Edinburgh Type: general – SubjectFull: ALZHEIMER'S disease Type: general – SubjectFull: SECONDARY prevention Type: general – SubjectFull: APOLIPOPROTEIN E4 Type: general – SubjectFull: SCIENTIFIC community Type: general – SubjectFull: DRUGS Type: general – SubjectFull: NEW trials Type: general Titles: – TitleFull: The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Saunders, Stina – PersonEntity: Name: NameFull: Gregory, Sarah – PersonEntity: Name: NameFull: Clement, Matthew H. S. – PersonEntity: Name: NameFull: Birck, Cindy – PersonEntity: Name: NameFull: van der Geyten, Serge – PersonEntity: Name: NameFull: Ritchie, Craig W. IsPartOfRelationships: – BibEntity: Dates: – D: 22 M: 11 Text: 11/22/2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 16642295 Numbering: – Type: volume Value: 13 Titles: – TitleFull: Frontiers in Neurology Type: main |
| ResultId | 1 |